Foghorn Therapeutics (FHTX) Debt to Equity (2019 - 2020)
Foghorn Therapeutics (FHTX) recorded quarterly Debt to Equity of $0.13 in Q4 2020, up 221.19% quarter-over-quarter from -$0.11 in Q3 2020, and up 178.3% on a YoY basis from $0.05 in Q1 2020.
Foghorn Therapeutics (FHTX) Debt to Equity (2019 - 2020) Analysis & Trends
Foghorn Therapeutics' Debt to Equity history runs 2 years deep, the most recent figure standing at $0.13 for Q4 2020.
- In Q4 2020, Debt to Equity rose 178.3% year-over-year to $0.13; the TTM figure through Dec 2020 stood at $0.13 (up 178.3% YoY), while the FY2020 annual figure was $0.13, up 178.3% from the prior year.
- Debt to Equity was $0.13 for Q4 2020 at Foghorn Therapeutics, up from -$0.11 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.13 in Q4 2020 to a low of -$0.17 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.32 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Foghorn Therapeutics | 282.33 Mn | 193.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 0.13 |
| Sep 30, 2020 | -0.11 |
| Dec 31, 2019 | -0.17 |